Comment
doi: 10.1016/S1470-2045(09)70110-X.
EGFR testing in lung cancer is ready for prime time
Affiliations
- PMID: 19410185
- DOI: 10.1016/S1470-2045(09)70110-X
Item in Clipboard
Comment
EGFR testing in lung cancer is ready for prime time
Lancet Oncol.
2009 May.
No abstract available
Comment on
-
Should we be surprised at the paucity of response to EGFR inhibitors?Lancet Oncol. 2009 May;10(5):522-7. doi: 10.1016/S1470-2045(09)70034-8. Lancet Oncol. 2009. PMID: 19410197 Review.
Similar articles
-
Targeting EGFR in non-small-cell lung cancer.N Engl J Med. 2005 Jul 14;353(2):200-2. doi: 10.1056/NEJMe058113. N Engl J Med. 2005. PMID: 16014890 No abstract available.
-
[I. What is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer?].Gan To Kagaku Ryoho. 2015 Aug;42(8):931-4. Gan To Kagaku Ryoho. 2015. PMID: 26353389 Japanese. No abstract available.
-
Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives.Future Oncol. 2017 Feb;13(3):201-204. doi: 10.2217/fon-2016-0325. Epub 2016 Sep 14. Future Oncol. 2017. PMID: 27624407 No abstract available.
-
Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.Expert Opin Pharmacother. 2010 Oct;11(14):2363-89. doi: 10.1517/14656566.2010.498581. Expert Opin Pharmacother. 2010. PMID: 20586711 Review.
-
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.Cancer Treat Rev. 2013 Dec;39(8):839-50. doi: 10.1016/j.ctrv.2013.05.001. Epub 2013 Jun 12. Cancer Treat Rev. 2013. PMID: 23768755 Review.
Cited by
-
Targeted therapies and immunotherapy in non-small-cell lung cancer.Ecancermedicalscience. 2016 Jun 23;10:648. doi: 10.3332/ecancer.2016.648. eCollection 2016. Ecancermedicalscience. 2016. PMID: 27433281 Free PMC article. Review.
-
Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients.J Thorac Dis. 2019 Sep;11(9):3712-3720. doi: 10.21037/jtd.2019.09.36. J Thorac Dis. 2019. PMID: 31656643 Free PMC article.
-
Clinical Challenge of Two Competing Targetable Mutations in Non-Small-Cell Lung Cancer: A Case Report.Diagnostics (Basel). 2023 Oct 2;13(19):3112. doi: 10.3390/diagnostics13193112. Diagnostics (Basel). 2023. PMID: 37835855 Free PMC article.
-
Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance.J Pers Med. 2014 Jun 25;4(3):297-310. doi: 10.3390/jpm4030297. J Pers Med. 2014. PMID: 25563355 Free PMC article. Review.
-
Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib.J Thorac Dis. 2018 May;10(5):E359-E363. doi: 10.21037/jtd.2018.04.162. J Thorac Dis. 2018. PMID: 29997994 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
